Cost effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China.
CONCLUSION: It is recommended that the price of utidelone would be less than $18.5 per 30mg in order to obtain cost-effectiveness for metastatic breast cancer patients resistant to anthracyclines and taxanes treatment in China.
PMID: 30808230 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | China Health | Clinical Trials | Economics | Health Management | Xeloda